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BACKGROUND. Loss-of-function of Pax2 results in severe defects of the male reproductive
system, and Pax2 expression is detected in mouse prostate lobes and human prostatic can-
cers. However, the role for Pax2 in prostate development remains poorly understood.
METHODS. The expression of Pax2 was examined by in situ hybridization at various devel-
opmental stages. Urogenital sinuses were dissected out at E18.5 from mouse Pax2 mutants
and controls, cultured in vitro or grafted under the renal capsule of CD1 nude mice. The
expression of prostate developmental regulatory factors was analyzed by semi-quantitative
real-time PCR or immuohistochemistry.
RESULTS. Pax2 is expressed in the epithelial cells of prostate buds. Loss-of-function of Pax2
does not affect the initiation of prostatic buds, but in vitro culture assays show that the pros-
tates of Pax2 mutants are hypomorphic and branching is severely disrupted compared to
controls. RT-PCR data from Pax2 mutant prostates demonstrate increased expression levels
of dorsolateral prostate marker MSMB and ventral prostate marker SBP and dramatically
reduced expression levels of anterior prostate marker TGM4.
CONCLUSIONS. Pax2 is essential for mouse prostate development and regulates prostatic
ductal growth, branching, and lobe-specific identity. These findings are important for under-
standing the molecular regulatory mechanisms in prostate development. Prostate 72: 217–224,
2012. # 2011 Wiley Periodicals, Inc.
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INTRODUCTION
As a male accessory exocrine secretory sex gland,
the prostate originates from the urogenital sinus
(UGS), a subdivision of the cloaca. Mouse prostate
epithelial buds initiate and grow out from the epi-
thelium of the UGS and protrude into the surround-
ing mesenchyme of the UGS at approximately
embryonic day 16 (E16). After birth, prostatic buds
continue to develop and undergo numerous branch-
ing events. After branching morphogenesis, the
mature prostate consists of three lobes, the anterior
prostate (AP, also named the coagulating gland), the
dorsolateral prostate (DLP), and the ventral prostate
(VP) [1]. Several markers of prostate lobe-specific epi-
thelial identities have been verified in recent studies,
such as Renin1 (Ren1) or Transglutaminase 4 (TGM4)
for the AP, Probasin (Pbsn), and Microseminoprotein-
b (MSMB) for the DLP and Spermine-binding protein
(SBP) for the VP [2,3].
Androgens, expressed in the epithelium, activate
androgen receptors (AR) in the mesenchyme to
induce early prostate morphogenesis. AR expression
is detected only in the urogenital sinus mesenchyme
(UGM) at early stages of prostate development, and is
critical for prostate development [4–6]. Estrogens are
also involved in prostate growth and differentiation
[7,8].
In addition to sex hormones, a variety of other
factors are known to regulate aspects of prostate
Grant sponsor: NIH; Grant number: DK077045.
Ben Xu and Arun Hariharan contributed equally to this work.
*Correspondence to: Dr. Deneen M. Wellik, University of Michigan
Medical Center, 109 Zina Pitcher, 2053 BSRB, Ann Arbor, MI 48109-
2200. E-mail: dwellik@umich.edu
Received 11 March 2011; Accepted 28 April 2011
DOI 10.1002/pros.21424
Published online 18 May 2011 in Wiley Online Library
(wileyonlinelibrary.com).
 2011WileyPeriodicals,Inc.
development. The epithelially expressed transcription
factor Nkx3.1 is among the first factors to be tran-
scriptionally activated by androgens. Nkx3.1 is critical
for prostatic ductal branching and differentiation and
also play important roles in carcinogenesis [9–11].
Foxa1 is expressed exclusively in the prostate epi-
thelium and regulates prostate ductal morphogenesis
by binding to a highly conserved 37 bp enhancer of
the Hoxb13 gene, which is also required for normal
prostate differentiation [12–14]. In addition, some sig-
naling molecules expressed in prostate epithelial cells,
such as Sonic hedgehog (Shh), also impact prostate
growth and epithelial differentiation [15,16]. During
prostate development, epithelial–mesenchymal inter-
actions are important for prostate morphogenesis and
differentiation, and mesenchymally expressed factors,
including Fgf10, Bmp4, and Sfrp1, play key roles in
prostate growth [17–20].
Pax2 belongs to 1 of 9 members of the paired box
(Pax) transcription factor family and is required for
kidney development [21–23]. Expression of Pax2
during normal prostate development and in human
prostatic cancers has been characterized, and its
expression can be repressed by androgens [24,25].
Urogenital defects in mice mutant for Pax2 have been
reported, but defects in prostate cannot be easily
examined at embryonic stages [26]. Here, we reported
analyses of the role of Pax2 in prostate morphogen-
esis. In vitro organ culture assays show ductal branch-
ing of Pax2 mutant prostate is perturbed and full
development of mature prostatic ducts is inhibited.
Markers of prostate lobe-specific epithelial identities
are severely disrupted. Expression levels of DLP
marker MSMB and VP marker SBP are dramatically
increased and expression of AP marker TGM4 is
essentially absent in mutant prostatic tissues. Taken
together, these results indicate that Pax2 gene plays
essential roles in prostate development.
MATERIALSANDMETHODS
InSituHybridization
UGS were collected at different stages of gestation,
fixed in 4% paraformaldehyde, embedded into Tis-
sue-TEK O.C.T. compound embedding medium and
sectioned (12 mm). Standard in situ hybridization was
performed by using digoxygenin-labeled antisense
RNA probes as previously reported [27,28].
ProstateOrganCulture andRenal
CapsuleGrafting
Pax2 mutant mice used in this study were
reported previously [26]. In vitro prostate culture was
performed as previously described [29]. E18.5 UGS
from Pax2 mutants and their littermate controls were
dissected out and placed on 0.4 mm Millicell filters
(Millipore) in six-well plates with DMEM media con-
taining 2% ITS (Insulin, Transferrin and Selenious
Acid; Invitrogen), 25 mg/ml gentamycin, 0.25 mg/ml
amphotericin B, and 108 M 5a-dihydrotestosterone
(DHT) for 7 days. Media was replaced every 2 days.
At least five separate samples from Pax2 mutants and
controls were analyzed in this study.
For in vivo kidney capsule grafts, UGS from Pax2
mutants or their littermate controls were dissected
from E18.5 embryos and seminal vesicles were
removed. Tissues were then grafted under the renal
capsule of at least 8-week-old CD1 male nude mice as
described (http://mammary.nih.gov/tools/mouse-
work/Cunha001/index.html). Tissues were collected
after 1 month.
Immunohistochemisty
Tissues were fixed overnight in 4% paraformalde-
hyde, embedded into Tissue-TEK O.C.T. compound
embedding medium, and sectioned (12 mm). Tissue
sections were incubated overnight at 48C with goat
anti-E-Cadherin antibody (1:100, R&D), guinea pig
anti-CK8/18 antibody (1:50, American Research
Products), and/or Rabbit anti-P63 antibody (1:50,
Santa Cruz), rinsed with PBS-Triton (0.1%), and incu-
bated with relevant secondary antibodies for 2–3 hr
at room temperature. Images were taken on
Olympus BX-51 microscope with an Olympus DP70
Camera.
Real-TimePCR
RNA was isolated from pooled E18.5 UGS (n ¼ 3)
or individual grafted UGS tissue with the Qiagen
RNeasy Micro kit (Qiagen). Reverse transcription was
performed containing 1 mg total RNA, 1 mM dNTP
mix, 50 ng random hexamers, 5 mM DTT, and 200 U
Superccript II reverse transcriptase (Invitrogen). Real-
time PCR was carried out by using FastStart Univer-
sal SYBR Green Master (Roche). Relative expression
values were calculated as 2DDCt and values of con-
trols were normalized to 1. Primers used in our stud-
ies are listed in Table I.
Hematoxylin andEosin Staining
Embryos at E18.5 were fixed overnight at 48C in
10% formalin solution, dehydrated by graded ethanol,
and stored in 70% ethanol. Embryos were embedded
into paraffin, sectioned at 5 mm and stained with
H&E [30].
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RESULTS
Pax2ExpressionPatterninUGS
We first examined the spatial and temporal expres-
sion profile of Pax2 gene in the UGS. In situ hybridiz-
ation data showed that Pax2 gene is robustly
expressed in epithelial cells of urogenital sinus, semi-
nal vesicles, and vas deferens (Fig. 1A). Weak Pax2
staining can be observed in epithelial cells of growing
prostate buds at E18.5 (Fig. 1A). Expression levels
become stronger by P4 in epithelial cells of the pros-
tate and are maintained in the urogenital sinus, semi-
nal vesicles, and vas deferens (Fig. 1B). These data are
consistent with previous reports [24], and suggest
that the Pax2 gene plays pivotal roles in mouse pros-
tate development.
Pax2MutantEmbryosExhibitNormal
ProstaticBud Initiation
To begin to evaluate Pax2 function in mouse pros-
tate development, we sectioned through the uro-
genital systems of Pax2 mutants and littermate
controls at E18.5 and analyzed the phenotypes in the
urogenital systems by paraffin sectioning and H&E
staining. Sections through E18.5 Pax2 male mutants
(n ¼ 6) show that the vas deferens and seminal
vesicles are absent, though the prostate buds initiate
normally in mutants compared to controls (n ¼ 4;
Fig. 2). These results are consistent with previous
reports [26] and show that Pax2 is not involved in the
early initiation of prostatic budding, but does not
exclude a later role for Pax2 in prostate development.
TABLE I. PrimersUsedinThisResearchAreListed
Primer Forward sequence Reverse sequence Size (bp)
GAPDH TGTCAGCAATGCATCCTGCA CCGTTCAGCTCTGGGATGAC 240
MSMB TGTCTGATGACTGCATGGATG GCTCAAAGGCCTAGTAGCGTT 131
SBP CAGAGCCCAGAATGTCCTG AAGCCCTTGATGAACTTGAA 121
TGM4 ATCCACGGCCAAGAATCAAGG CTGCAATGATGAACCCTCCAA 109
Shh CAATTACAACCCCGACATCA GGTCACTCGCAGCTTCACTCC 142
Bmp4 GATTGGCTCCCAAGAATCAT CCTAGCAGGACTTGGCATAA 114
Fgf10 CGTCAAAGCCATCAACAGCA CCTCTATTCTCTCTTTCAGCTTACAGT 107
Foxa1 CCATGAACAGCATGACTGCG TCGTGATGAGCGAGATGTAGGA 267
Hoxb13 GATGTGTTGCCAAGGTGAAC GAGGAGGGTGCTGGACACTGG 83
Nkx3.1 CCGAGTCTGATGCACATTTTGAG CTGTGGCTGCTTGGTGACCTG 95
Sfrp1 TCATGCAGTTCTTCGGCTTCTACT TTGTCGCATGGAGGACACACGGTTGTACC 145
Sfrp2 AGGACAACGACCTCTGCATCCC TTCTTGGTTTTGCAGGCTTCAC 97
Fig. 1. Pax2 is expressedindevelopingprostate epithelialbuds.Pax2 transcripts arevisible inepithelialcells of seminalvesicles andvasdefer-
ens at E18.5 (A) and P4 (B).Weak staining signals are observed in epithelial cells of E18.5 prostate buds (A, arrowheads) and Pax2 expression
in epithelial cells of prostate buds becomes stronger at P4 (B) compared to those at E18.5 (A). SV, seminal vesicles; VD, vas deferens;
Ur,urethra.
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EarlyDevelopmentalRegulatoryGenesAre
UnalteredinPax2MutantUGS
Many genes involved in prostatic ductal branching
and morphogenesis are well studied (reviewed in
Ref. 1). To explore the molecular mechanisms of Pax2
in prostate development and characterize defects in
Pax2 mutants at early stages, expression levels of
genes functioning in prostate development were
examined in E18.5 Pax2 mutant UGS. Real-time PCR
data showed expression levels of Shh, Fgf10, Foxa1,
Hoxb13, Nkx3.1, Sfrp1, and Sfrp2 are unaltered in
E18.5 Pax2 mutant UGS (Fig. 3). Bmp4 expression is
reduced in Pax2 mutants at this stage (Fig. 3), indicat-
ing possible effects on this pathway.
TheProstaticDuctalBranching
ofPax2Mutants IsDisrupted
Since Pax2 mutants do not survive postnatally
and the initiation of prostatic buds of Pax2 mutants is
normal, in vitro tissue culture was employed to inves-
tigate the role of Pax2 in later prostate development.
Tissues were collected at E18.5 and cultured for
7 days. Pax2 mutant prostatic tissues were smaller
and less developed than controls (Fig. 4A,B). Sections
through these tissues demonstrate that prostatic ducts
form but ductal branching is significantly decreased
in Pax2 mutants (Fig. 4C,D). Ducts in Pax2 mutants
are smaller than controls and most of prostate buds
are rudimentary (Fig. 4D). Cultured Pax2 heterozy-
gotes do not exhibit any phenotypic abnormalities
in these experiments (data not shown). These data
indicate that Pax2 is essential for postnatal prostate
growth and ductal branching.
To further investigate the role of Pax2 in prostate
maturation and differentiation at later stages, we
employed renal capsule graft assays to allow an
examination of continued development. In these
experiments, UGS were dissected out at E18.5, grafted
under the renal capsule of CD1 nude mice, and
allowed to develop for 1 month after grafting. At later
stages of prostate maturation, as prostatic ducts begin
to canalize, the epithelium is divided into two differ-
ent types of cells including basal epithelial cells
(P63þ) and columnar luminal epithelial cells (CK8/
18þ), and ducts are normally surrounded by multiple
Fig. 2. Prostatephenotypes of Pax2mutants. Serial sections showPax2mutantshave thenormal initiation ofprostatebuds (blank arrow-
heads) and lack seminal vesicles and vas deferens (B,D, and F) compared to controls (A,C, and E). SV, seminal vesicles; VD, vas deferens;
Ur,urethra;DLP,dorsolateralprostaticbuds;VP,ventralprostaticbuds;AP,anteriorprostaticbuds.
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cell layers of smooth muscle cells (a actinþ, SMA;
reviewed in Ref. 1, Fig. 5A,C,E). In grafted Pax2
mutant tissues (n ¼ 3), normal smooth muscle cells
surround prostatic ducts (Fig. 5B), epithelial cells
stain positively for E-Cadherin, and CK8/18 and P63
expression is observed (Fig. 5B,D,F), but there is an
overabundance of epithelial cells and many of these
cells protrude into ductal lumen and appear highly
disorganized (Fig. 5B,D). These data show that Pax2
gene plays key roles in prostatic epithelial cell pro-
liferation and organization.
To evaluate prostatic epithelial cell differentiation
in Pax2 mutants and control tissues, markers of pros-
tate lobe-specific epithelial identities were employed.
Fig. 3. Expression of prostate developmental regulatory genes in Pax2 mutant UGS. Normal expression of Shh, Fgf10, Foxa1, Hoxb13,
Nkx3.1, Sfrp1, and Sfrp2 in E18.5 Pax2mutantUGSwere observed.BMP4 expression is slightlyreduced in Pax2mutantUGS at E18.5.Relative
expression is shown as mean  SEM for at least three samples. Expression values of controls were normalized to1. Significant differences
betweengroupsweredeterminedbyStudents’t-test.Asteriskindicates significantdifferences fromcontrols (P < 0.05).
Fig. 4. Pax2 mutant UGS collected at E18.5 and cultured for 7 days in vitro. Prostatic tissues in Pax2 mutants (B andD) are smaller than
controls (A andC).H&E staining of sections through cultured prostate tissues show Pax2 mutant prostatic ducts do not fully differentiate,
andductalbranchingisinhibited (D).
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Previous reports have confirmed Microseminopro-
tein-b (MSMB) as a marker for the DLP, SBP as a
marker for the VP, and Transglutaminase 4 (TGM4)
as a marker for the AP [3]. The expression of MSMB
and SBP displays over 15- and 25-fold increases in
Pax2 mutants, respectively (Fig. 6A,B). However, the
expression of AP marker TGM4 is dramatically
reduced in Pax2 mutants compared to controls
(Fig. 6C). These results demonstrate that Pax2 is
required for the normal differentiation of prostatic
epithelial cells and suggest Pax2 plays a role in lobe-
specific identity.
DISCUSSION
Our data show that Pax2 plays an important role in
prostatic epithelial development and differentiation
[24]. However, we did not observe defects in initial
prostate buds in Pax2 mutants, and early patterning
factors expressed in prostate epithelial cells, such as
Foxa1, Hoxb13, and Nkx3.1 [9,12,13], exhibit the nor-
mal expression in Pax2 mutant UGS, consistent with
relatively normal phenotypes of Pax2 mutant prostate
buds. Pax2 belongs to the Class III subgroup of Pax
family members, consisting of Pax2, Pax5, and Pax8.
Fig. 5. Immunohistochemical stainingof grafed Pax2mutantprostates.The E18.5UGSwere collected andgraftedunder the renal capsule
of CD1nude mice for1month.Grafted tissue sections were immunostained for SMA, E-Cadherin,CK8/18, and P63. Epithelial cells stained
positively for E-Cadherin, CK8/18, and P63 are observed in mutant tissues (B, D, and F), but many epithelial cells protrude into some
mutantductal lumensandshowedahighlevelofdisorganizationcomparedto controls (A,C, andE).
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Pax5 and Pax8 genes are also expressed in E16.5 UGS
[24], and it is likely that they function redundantly in
early prostate development with Pax2. The generation
of compound mutants of Pax2, Pax5, and Pax8 will
allow this hypothesis to be tested.
In our present analyses, we found that Pax2 func-
tion is important for postnatal stage prostatic duct
growth and branching. Previous studies have shown
that other factors are involved in prostatic duct
development, such as epithelium-derived Shh and
mesenchyme-derived Bmp4, which are required for
restricting prostatic ductal growth and morphogen-
esis [15,16,19], and mesenchyme-derived Fgf10, which
is involved in promoting ductal growth [17]. Expres-
sion of Shh and Fgf10 was unchanged in our Pax2
mutant UGS at E18.5, showing that Pax2 does not
appear to function upstream of these signaling path-
ways to promote prostate growth. A slight decrease
of BMP4 expression in Pax2 mutants suggests
possible interactions with this pathway.
TGM4, MSMB, and SBP encode androgen-depend-
ent prostatic secretory proteins, and are used as
markers of prostate lobe-specific epithelial identity
[2,3]. In our grafted Pax2 mutant prostate tissues,
increased expression levels of MSMB and SBP and
reduced expression levels of TGM4 indicate a signifi-
cant defect in establishing prostate lobe identities.
Usually, these genes are expressed in completely
developed and quiescent secretory cells. Our data
suggest that epithelial cells in the DLP and VP of Pax2
mutants over-proliferate, and epithelial cells in AP of
Pax2 mutants do not fully develop or differentiate.
Although anterior prostatic buds are normally
initiated in Pax2 mutants, later development or differ-
entiation of AP in Pax2 mutants is severely affected.
This may be related to previously reported defects in
the other anterior accessory gland, seminal vesicles,
and vas deferens.
The Pax2 phenotype shows partial similarities to
Sfrp1 null mutants [18]. In Sfrp1 mutants, markers for
all these prostate lobe-specific identity are highly up-
regulated, suggesting over-proliferation of epithelial
cells [18]. For Pax2 mutants, the up-regulation is only
observed for the DLP and VP. Pax2 mutants exhibit
the additional phenotype of an identity defect in the
AP. However, Sfrp1 and Sfrp2 expression are not sig-
nificantly altered in our Pax2 mutants, suggesting
different mechanisms for Pax2 in prostate develop-
ment or these genes are functioning in parallel.
In conclusion, our data show that Pax2 plays essen-
tial roles in normal prostate growth, ductal branching,
and epithelial cell differentiation. These findings
will contribute to understanding molecular regulatory
mechanisms in normal prostate patterning and abnor-
mal growth of prostate cancer.
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